AOD 9604 research hit a wall in people.
The idea was to change how the body handles fat. The human weight-loss result didn’t deliver on the early promise.
Follow the idea through to the result.
AOD-9604 is a man-made fragment based on part of human growth hormone. Researchers wanted its proposed effects on fat without the whole hormone’s growth effects. That was the plan. Whether it helped people lose weight was another question.
Use
fat for fuel
Fat oxidation means using fat for energy. Mouse experiments found changes in that process, but a revealing detail gets lost in “fat burning” claims. Mice bred without a signal receiver called the beta-3 adrenergic receptor still used more fat after a dose. But they lacked the weight response to repeated treatment seen in mice with that receptor.
A change in fuel use doesn’t necessarily add up to a change in body weight. And these were mice.
Store
what the human trial told us
The main obesity trial did not show a clear weight-loss advantage over a dummy treatment, and development for obesity stopped. The published human trial report belongs in the story alongside the mouse work. A clever explanation of how something might work can’t replace the result in people.
We wouldn’t describe AOD-9604 as a proven human fat-loss treatment. The disappointing finding matters more to that question than the appealing nickname.
Respond
to limited safety information
The oral obesity trials reported tolerability similar to the dummy treatment, with treatment lasting no more than 24 weeks. That doesn’t rule out rare problems or settle long-term safety. It doesn’t establish the safety of an injected preparation.
AOD-9604 has no FDA approval. Its entry in FDA’s withdrawn-nominations table still carries safety concerns. A withdrawn request isn’t permission for pharmacies to make medicines from it.
“Fat burning” isn’t the finish line.
If your question is about losing body fat, the useful evidence needs to measure that change in people. AOD-9604’s failed weight-loss result gives us a reason to be skeptical of sweeping claims. It doesn’t choose another treatment for you. It tells us what this one hasn’t demonstrated.
Give the claim a closer look.
Ask whether a claim concerns fuel use, body weight or body fat. Then check whether the finding came from mice or people. Those small distinctions change the answer a lot.
The AOD 9604 vs semaglutide comparison explains why we give their human evidence different weight. The questions page covers why combining the names doesn’t fill the gaps.